111 related articles for article (PubMed ID: 24842570)
1. Flare of calcinosis despite rituximab therapy.
Hurabielle C; Allanore Y; Kahan A; Avouac J
Semin Arthritis Rheum; 2014 Oct; 44(2):e5-6. PubMed ID: 24842570
[No Abstract] [Full Text] [Related]
2. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature.
Daoussis D; Antonopoulos I; Liossis SN; Yiannopoulos G; Andonopoulos AP
Semin Arthritis Rheum; 2012 Jun; 41(6):822-9. PubMed ID: 22221908
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-induced regression of CREST-related calcinosis.
de Paula DR; Klem FB; Lorencetti PG; Muller C; Azevedo VF
Clin Rheumatol; 2013 Feb; 32(2):281-3. PubMed ID: 23179007
[TBL] [Abstract][Full Text] [Related]
4. Is rituximab an effective treatment of refractory calcinosis?
Dubos M; Ly K; Martel C; Fauchais AL
BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27247203
[TBL] [Abstract][Full Text] [Related]
5. Effects of rituximab therapy on elastic properties of vascular wall in patients with progressive systemic sclerosis.
Maslyanskiy AL; Lapin SV; Kolesova EP; Penin IN; Cheshuina MD; Feist E; Konradi AO
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-228. PubMed ID: 24480389
[No Abstract] [Full Text] [Related]
6. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Haug-Rost I; Braun J; Sieper J
Ann Rheum Dis; 2013 Feb; 72(2):305-6. PubMed ID: 22887847
[No Abstract] [Full Text] [Related]
7. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab.
McGonagle D; Tan AL; Madden J; Rawstron AC; Rehman A; Emery P; Thomas S
Rheumatology (Oxford); 2008 Apr; 47(4):552-3. PubMed ID: 18281368
[No Abstract] [Full Text] [Related]
9. [Connective tissue diseases].
Lorenz HM
Dtsch Med Wochenschr; 2012 Mar; 137(13):661-3. PubMed ID: 22434176
[No Abstract] [Full Text] [Related]
10. Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis?
Mease PJ
J Rheumatol; 2012 Dec; 39(12):2235-7. PubMed ID: 23204311
[No Abstract] [Full Text] [Related]
11. The efficacy of rituximab in refractory myositis: the jury is still out.
de Visser M
Arthritis Rheum; 2013 Feb; 65(2):303-6. PubMed ID: 23125047
[No Abstract] [Full Text] [Related]
12. The updated guidelines on the use of rituximab in rheumatoid arthritis.
Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME
Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350
[No Abstract] [Full Text] [Related]
13. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years.
Yamamoto M; Awakawa T; Takahashi H
Ann Rheum Dis; 2015 Aug; 74(8):e46. PubMed ID: 25862615
[No Abstract] [Full Text] [Related]
14. Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19.
Bacconnier L; Combe B; Canaud B; Morel J
Rheumatology (Oxford); 2010 Dec; 49(12):2452-3. PubMed ID: 20591832
[No Abstract] [Full Text] [Related]
15. Immunologic reconstitution after rituximab in systemic lupus erythematosus: why should we care?
Anolik J
J Rheumatol; 2011 Apr; 38(4):587-9. PubMed ID: 21459953
[No Abstract] [Full Text] [Related]
16. Treatment approaches in primary Sjogren syndrome.
Vissink A; Kallenberg CG; Bootsma H
JAMA; 2010 Nov; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
[No Abstract] [Full Text] [Related]
17. Refractory anti-synthetase syndrome treated with rituximab.
Ball EM; Savage EM; Pendleton A
Rheumatology (Oxford); 2010 May; 49(5):1013. PubMed ID: 20032227
[No Abstract] [Full Text] [Related]
18. Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis.
Chimenti MS; Teoli M; Di Stefani A; Giunta A; Esposito M; Perricone R
Eur J Dermatol; 2013 Apr; 23(2):273-4. PubMed ID: 23557629
[No Abstract] [Full Text] [Related]
19. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
[No Abstract] [Full Text] [Related]
20. Discordant response to rituximab in a systemic sclerosis patient with associated myositis.
Fabri M; Hunzelmann N; Krieg T; Rubbert A
J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S127-8. PubMed ID: 18489049
[No Abstract] [Full Text] [Related]
[Next] [New Search]
